CD22 and lymphoma: These findings support our hypothesis that expression of a truncated human CD22 that lacks the signal transduction elements encoded by Exons 12–14, as it occurs in CD22ΔE12+ ALL, would confer B-lineage leukemia and lymphoma cells with a selective growth advantage.